Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.

Oral Oncol 2013 Jan 1;49(1):55-9. Epub 2012 Aug 1.

Department of Clinical Oncology, St. James's Institute of Oncology, Beckett Street, Leeds LS9 7TF, United Kingdom.

Objectives: The optimal management of the N3 neck in head and neck squamous cell carcinoma (HNSCC) remains controversial. We report the outcomes of patients with N3 disease treated with a strategy of concurrent chemo-radiotherapy (CRT)±induction chemotherapy (ICT) without a planned neck dissection.

Materials And Methods: Forty patients with HNSCC N3 disease treated between January 2004 and December 2010 were retrospectively identified. Inclusion criteria for the study were: non-nasopharyngeal HNSCC, N3 nodal disease, intention to treat with CRT±ICT.

Results: Median age was 60 (range 39-74). Median follow up was 32 months (range 8-88). 34 (85%) of patients received ICT. 35 patients received cisplatin-CRT, 4 carboplatin-CRT and 1 patient was treated with radiotherapy alone due to ICT toxicity. 27 (67.5%) patients had a complete response (CR) to CRT. 5 (12.5%) patients had an incomplete response in both the primary and nodal sites. 8 (20%) patients had a CR in the primary site but incomplete in the nodal regions. The crude rate of regional failure following a CR was 3/27 (11.2%). Isolated regional failure occurred in 1/27 (3.7%) patients who had achieved a CR post-CRT. 3 year overall survival, disease free survival, locoregional control, local control and regional control in the whole cohort were 51.4%, 49.6%, 65.7%, 77.3%, 69.3%, and in patients with a CR were 73.3%, 70.0%, 86.6%, 90.5% and 91.7% respectively.

Conclusion: Isolated regional nodal failure is rare following a complete response to CRT for N3 HNSCC managed without a planned neck dissection.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2012.07.010DOI Listing
January 2013

Publication Analysis

Top Keywords

planned neck
12
patients
9
patients received
8
cell carcinoma
8
neck dissection
8
complete response
8
isolated regional
8
response crt
8
squamous cell
8
disease treated
8
regional failure
8
head neck
8
neck squamous
8
neck
6
range 8-88
4
months range
4
cisplatin-crt carboplatin-crt
4
follow months
4
received cisplatin-crt
4
cohort 514%
4

Similar Publications

Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.

Int J Radiat Oncol Biol Phys 2004 Apr;58(5):1418-23

Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.

Purpose: Neck dissection has traditionally played an important role in the treatment of patients with squamous cell carcinoma of the head and neck who present with regionally advanced neck disease (N2-N3). Radiotherapy and concurrent chemotherapy improves overall survival in advanced head-and-neck cancer compared with radiotherapy alone. The necessity for postchemoradiation neck dissection is controversial. Read More

View Article and Full-Text PDF
April 2004

The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.

Clin Oncol (R Coll Radiol) 2013 Nov 13;25(11):647-53. Epub 2013 Aug 13.

Department of Clinical Oncology, St. James's Institute of Oncology, Leeds, UK.

Aims: The role of induction chemotherapy (ICT) for head and neck squamous cell carcinoma (HNSCC) is controversial. The aim of the study was to assess the benefit of ICT with docetaxel, cisplatin and 5-fluorouracil (5-FU) (TPF) when combined with concurrent cisplatin chemoradiotherapy (CRT) for HNSCC.

Materials And Methods: Patients with HNSCC treated between January 2005 and December 2010 with radical intent with either TPF or cisplatin and 5-FU (PF) ICT and documented intention to proceed with concurrent cisplatin CRT were identified retrospectively. Read More

View Article and Full-Text PDF
November 2013

Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.

Auris Nasus Larynx 2015 Apr 8;42(2):150-5. Epub 2014 Dec 8.

Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. Electronic address:

Objective: The treatment of head and neck squamous cell carcinoma (HNSCC) with N3 (>6cm) lymph nodes remains difficult, and the best treatment strategy has not been elucidated. The aim of this study was to evaluate the outcomes of various treatment modalities.

Methods: Sixty-nine patients with HNSCC and N3 neck disease treated with definitive therapy in our institute between 1987 and 2013 were included in the analysis. Read More

View Article and Full-Text PDF
April 2015

A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.

Int J Radiat Oncol Biol Phys 2012 Jul 2;83(3):994-9. Epub 2011 Dec 2.

Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305-5847, USA.

Purpose: To assess the role of a planned neck dissection (PND) after sequential chemoradiotherapy for patients with head-and-neck cancer with N2-N3 nodal disease.

Methods And Materials: We reviewed 90 patients with N2-N3 head-and-neck squamous cell carcinoma treated between 1991 and 2001 on two sequential chemoradiotherapy protocols. All patients received induction and concurrent chemotherapy with cisplatin and 5-fluorocuracil, with or without tirapazamine. Read More

View Article and Full-Text PDF
July 2012